应用β肾上腺素能受体阻滞剂规范治疗冠心病的中国专家共识  

Chinese Expert Consensus Document on Appropriate Use of Beta-adrenergic Receptor Blocker in Patients With Coronary Heart Disease

作　　者：无 陈韵岱 董蔚[3] 汪京嘉 

机构地区：[1]应用β肾上腺素能受体阻滞剂规范治疗冠心病中国专家共识组 [2]中国人民解放军总医院第一医学中心 [3]解放军总医院第一医学中心 [4]中国医学科学院阜外医院

出　　处：《中国循环杂志》2020年第2期108-123,共16页Chinese Circulation Journal

摘　　要：β肾上腺素能受体阻滞剂(β受体阻滞剂)已被证实可降低无禁忌证冠心病患者的全因死亡和心血管死亡风险,而我国冠心病人群中β受体阻滞剂的应用存在明显不规范,主要体现为使用率低、使用剂量不足和长期治疗依从性差。该共识在《β肾上腺素能受体阻滞剂在心血管疾病应用专家共识》基础上,汇总了近年来出现的新证据,进一步细化患者分类,明确了冠心病患者β受体阻滞剂应用应遵循的“BETA”原则,即Beneficial assessment(获益评估)、Enough dosage(足量应用)、Timely usage(及时使用)、Adequate titration(充分滴定),就不同患者人群使用β受体阻滞剂的临床指征、用法用量、治疗目标和疗程给出了明确建议。Beta-adrenergic receptor blockers(β-blockers)have been proved to reduce the all-cause mortality and cardiovascular mortality in patients with coronary heart disease without contraindication.However,the role ofβ-blockers have been long unstandardized in clinical practice with a relatively low rate of usage,dosage and long-term treatment.This consensus is based on Expertise Consensus on Application ofβAdrenergic Receptor Blockers in Cardiovascular Diseases published in 2009.With novel agents and technologies update,recently merging evidence pooled and patient groups further detailed classified,this consensus clearify the‘BETA’principal forβ-blockers administration in clinical practice,including Beneficial assessment,Enough dosage,Timely usage,Adequate titration.According to different groups of patients,the clinical indication,dosage,target and duration ofβ-blockers are enunciated in this consensus.

关 键 词：Β受体阻滞剂 冠心病 慢病 二级预防 专家共识 

分 类 号：R541[医药卫生—心血管疾病]